The evidence framework for precision cancer medicine
暂无分享,去创建一个
[1] Christopher A. Miller,et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. , 2014, Cancer cell.
[2] L. Garraway,et al. Clinical implications of the cancer genome. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Milan Radovich,et al. Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers , 2016, Oncotarget.
[4] Amber M. Johnson,et al. A decision support framework for genomically informed investigational cancer therapy. , 2015, Journal of the National Cancer Institute.
[5] S. Chakradhar. Group mentality: Determining if targeted treatments really work for cancer , 2016, Nature Medicine.
[6] Masahiro Fukuoka,et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Rong Chen,et al. Integrating 400 million variants from 80,000 human samples with extensive annotations: towards a knowledge base to analyze disease cohorts , 2016, BMC Bioinformatics.
[8] J. Barretina,et al. Genomic medicine frontier in human solid tumors: prospects and challenges. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Razelle Kurzrock,et al. Dosing Three-Drug Combinations That Include Targeted Anti-Cancer Agents: Analysis of 37,763 Patients. , 2017, The oncologist.
[10] David Wholley,et al. Lung Master Protocol (Lung-MAP)—A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400 , 2015, Clinical Cancer Research.
[11] Rajendu Srivastava,et al. A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs , 2016, Journal of oncology practice.
[12] Nikhil Wagle,et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. , 2014, The New England journal of medicine.
[13] Razelle Kurzrock,et al. Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative , 2012, Clinical Cancer Research.
[14] R. Yelensky,et al. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. , 2016, Cancer research.
[15] I. Tannock,et al. Limits to Personalized Cancer Medicine. , 2016, The New England journal of medicine.
[16] Michael Bittner,et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. Blay,et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. , 2015, The New England journal of medicine.
[18] Razelle Kurzrock,et al. Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers , 2016, Oncotarget.
[19] Aleksandar Sekulic,et al. Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non–V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team , 2015, Molecular Cancer Therapeutics.
[20] S. Gabriel,et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. , 2014, Cancer discovery.
[21] Christine M. Micheel,et al. Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted Therapies , 2014, Clinical Cancer Research.
[22] Jeremy L Warner,et al. Identifying Health Information Technology Needs of Oncologists to Facilitate the Adoption of Genomic Medicine: Recommendations From the 2016 American Society of Clinical Oncology Omics and Precision Oncology Workshop. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Marie-Cécile Le Deley,et al. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. , 2017, Cancer discovery.
[24] Roman Rouzier,et al. Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials , 2015, Journal of the National Cancer Institute.
[25] C. Sander,et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Sante Tura,et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. , 2002, Blood.
[27] Marilyn M. Li,et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. , 2017, The Journal of molecular diagnostics : JMD.
[28] R. Kurzrock,et al. Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Jong-Hyeon Jeong,et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Jong-Hyeon Jeong,et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] P. Campbell,et al. Genomic Classification in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.
[32] R. Larson,et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. , 2002, Blood.
[33] E. Felip,et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.
[34] J. Brábek,et al. Limits to Precision Cancer Medicine. , 2017, The New England journal of medicine.
[35] Subha Madhavan,et al. Somatic cancer variant curation and harmonization through consensus minimum variant level data , 2016, Genome Medicine.
[36] W. Hahn,et al. Prospective enterprise-level molecular genotyping of a cohort of cancer patients. , 2014, The Journal of molecular diagnostics : JMD.
[37] M. Levis,et al. Midostaurin approved for FLT3-mutated AML. , 2017, Blood.
[38] Nicolas Servant,et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. , 2015, The Lancet. Oncology.
[39] Francisco Cervantes,et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.
[40] Funda Meric-Bernstam,et al. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] Benjamin S. Glicksberg,et al. Development and clinical application of an integrative genomic approach to personalized cancer therapy , 2016, Genome Medicine.
[42] R. Schilsky,et al. Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. , 2015, Journal of the National Cancer Institute.
[43] Levi A Garraway,et al. Genomics-driven oncology: framework for an emerging paradigm. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] L. Fang,et al. Clinical Pharmacology and Orphan Drugs: An Informational Inventory 2006–2010 , 2012, Clinical pharmacology and therapeutics.
[45] J Jack Lee,et al. Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] Vinay Prasad,et al. Perspective: The precision-oncology illusion , 2016, Nature.
[47] William Pao,et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.
[48] A. Hauschild,et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.
[49] Udayan Guha,et al. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] Suzanne Kamel-Reid,et al. A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer , 2015, Genetics in Medicine.
[51] Olivier Michielin,et al. Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.